Literature DB >> 15807189

Association of cardiac valve calcification and inflammation in patients on hemodialysis.

Dilek Torun1, Siren Sezer, Mehmet Baltali, Fatma Ulku Adam, Abdullah Erdem, Fatma Nurhan Ozdemir, Mehmet Haberal.   

Abstract

BACKGROUND/AIMS: This study investigates the possible relationship between inflammation and cardiac valve calcification (VC) in patients on hemodialysis (HD), and identifies risk factors for VC in this patient group.
METHODS: Seventy-nine patients on HD (mean age, 52.2 +/- 13.6 years; mean HD duration, 46.8 +/- 34.3 months) were assessed echocardiographically for the presence of VC. Systolic and diastolic blood pressure (BP) values were determined. The blood parameters studied in each case were hemoglobin, blood urea nitrogen, creatinine, calcium, phosphate, calcium-phosphorous (Ca x P) product, albumin, alkaline phosphatase, intact parathyroid hormone, total cholesterol, high-density lipoprotein, low-density lipoprotein, triglyceride, lipoprotein(a), fibrinogen, and C-reactive protein (CRP). The number of patients receiving vitamin D and calcium-containing phosphate binder was determined from records, and presence of diabetes mellitus was noted.
RESULTS: Cardiac VC was detected in 36 patients (46%). Five of these patients (6%) had mitral VC, 11 (14%) had aortic VC, and 20 (25%) had calcification of both valves. The patients with VC were significantly older than those without VC (60 +/- 11 vs. 43 +/- 15 years, respectively; P=.001). Compared with the group without VC, the group with calcification had significantly higher systolic (145.1 +/- 14.7 vs. 124.3 +/- 20.7 mmHg, P=.001) and diastolic BP (91.3 +/- 10.3 vs. 75.09 +/- 14.9 mmHg, P=.001); significantly higher phosphate (5.1 +/- 1.4 vs. 4.5 +/- 1.4 mg/dL, P=0.04), CaxP product (48.6 +/- 16.2 vs. 39.8 +/- 11.8, P=.01), lipoprotein(a) [28 (15, 45) vs. 16 (5,42) mg/dL, P=.04], fibrinogen (4.2 +/- 1.2 vs. 3.5-0.9, P=.005), and CRP levels [9 (4, 19) vs. 5 (3, 11) mg/L, P=.05]; and significantly longer HD duration [49 (27, 99) vs. 26 (17, 52) month, P=.01). Apart from age, duration of HD, systolic and diastolic BP, and Ca x P product, VC was associated with CRP (odds ratio, 1.151; P=.007) and fibrinogen (odds ratio, 1.119; P=.005).
CONCLUSIONS: The results confirm well-known risk factors for cardiac VC in HD patients, such as older age, longer HD duration, elevated BP, and high Ca x P product. In addition, they suggest that elevated levels of CRP and fibrinogen were associated with VC in the HD population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15807189

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  6 in total

Review 1.  Selection of artificial valve for the patients on hemodialysis.

Authors:  Hirofumi Takemura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-12-07

2.  Relationship between aortic valve sclerosis and left ventricular hypertrophy in chronic haemodialysis patients.

Authors:  Funda Turkmen; Ayse Emre; Ali Ozdemir; Can Sevinc; Emre Erisken; Kemal Yesilcimen
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

Review 3.  C-reactive protein in aortic valve disease.

Authors:  Pedro L Sanchez; Anna Maria Mazzone
Journal:  Cardiovasc Ultrasound       Date:  2006-10-16       Impact factor: 2.062

Review 4.  C-reactive protein in degenerative aortic valve stenosis.

Authors:  Pedro L Sanchez; AnnaMaria Mazzone
Journal:  Cardiovasc Ultrasound       Date:  2006-06-14       Impact factor: 2.062

5.  Association of the C-Reactive Protein Gene (CRP) rs1205 C>T Polymorphism with Aortic Valve Calcification in Patients with Aortic Stenosis.

Authors:  Ewa Wypasek; Daniel P Potaczek; Anetta Undas
Journal:  Int J Mol Sci       Date:  2015-10-09       Impact factor: 5.923

6.  Periodontal disease is an independent predictor of intracardiac calcification.

Authors:  Gregg S Pressman; Atif Qasim; Nitin Verma; Masami Miyamae; Kumiko Arishiro; Yasuhiro Notohara; Vitalie Crudu; Vincent M Figueredo
Journal:  Biomed Res Int       Date:  2013-09-11       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.